🔗 Share this article

As the United States continues making sweeping revisions to its immunization schedules, one figure appears somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by casting doubt on coronavirus vaccines in the pandemic and has focused upon possible fatalities after COVID-19 vaccination in her brief time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Vaccine Program

Health officials were set to unveil radical changes to the pediatric vaccination calendar in December, aligning the US with the Danish vaccine program, according to reports – a major change that would put the US out of step with many the global community with insufficient data for public health gain. The announcement has been postponed until the new year.

Rather than the director of the vaccine center, Dr. Høeg is set to present at the event. She was recently named acting director of the FDA’s CDER, the fifth person to lead the center this calendar year.

A Shift at the FDA

The acting appointment may indicate a tighter collaboration between the drug and vaccine centers as Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a renewed priority upon dismantling long-standing vaccines at the FDA.

Høeg has repeatedly called for discontinuing specific childhood vaccine recommendations in the US to become more similar to Denmark's approach, a country with nationalized medicine and a citizenry about the population of Wisconsin’s.

So far statements, she has persisted in emphasizing on vaccines – traditionally the domain of Dr. Prasad, director of the FDA’s vaccine center – rather than medication approval.

Doubts Over Expertise

Dr. Høeg has no obvious track record in medication creation, regulation or management, which has been customary for previous directors of the CBER. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in managing a sizeable institution. She is not an expert in industry regulation.”

Former commissioners of the center would “grasp laws and regulations and the science of pharmaceutical innovation”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the sort of resume that previous people who headed CBER have had.”

CDER has an enormous portfolio at the agency, Woodcock stated.

“Many people just pays attention on the new drug program, but the generic program clears a multitude of generic medications. There is also a biosimilars division, non-prescription drug unit and other areas, and every single one must be managed,” she explained. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Furthermore, a substantial administrative component to the job, which oversees more than 5,000 staff members. “It is a enormous management job, if you execute it properly,” the former official added.

Response and Contentious Programs

Regarding concerns about Høeg’s credentials and whether this selection indicates increased cooperation among FDA leaders on immunizations, a spokesperson responded that the “inquiries are based on flawed assumptions”.

“Her resume aligns with the functions of her position,” the official explained, citing the time Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg takes over the agency head's recently launched priority voucher program, a disputed one-day drug-approval program that reportedly troubled her predecessors. “How are these medications being selected for this expedited pathway? Who is making the calls?” Dr. Howard said. “There’s a lot of confidentiality going on at the FDA right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards less stringent oversight of all drugs, except for shots.”

Documented History on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if troubling, history, critics said. She authored a research paper using unconfirmed public submissions to estimate the incidence of heart inflammation after COVID-19 immunization. She consulted for the Florida top health official Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the new federal leadership encompassed revising regulations for recently developed shots and discontinuing “optional” vaccines, she remarked after the election on a audio program. At the FDA, Høeg has according to sources proposed excluding adolescent males from obtaining COVID-19 vaccines.

“She’s an complete true believer who starts off with her preconceived notions and tailors the evidence to accommodate the data in a highly misleading, untruthful way,” Dr. Howard said.

Taking Control and a “Push for Payback”

Høeg joined fellow dissenters, {like|